Skip to content
CLVT

Clarivate Plc

Clarivate Plc Q4 FY2024 earnings call

February 19, 2025 · fiscal period ended 2024-12

EPS · actual vs est

$0.21 / $0.20Beat +5.0%

Revenue · actual vs est

$663.0M / $601.1MBeat +10.3%
Ask about this call

Summary

Generated 2025-02-19

Management highlights

Pillars of VCP - Revenue optimization: Moving ProQuest to subscription and launching DRG Fusion in life science. - Sales execution: Attracting experienced sales leaders, optimizing reporting structure, realigning account management, and refocusing incentive models. - Product innovation: Leveraging academic AI in various products, enhancing Cortellis R&D platform, and launching AI patent search in IP. - Portfolio rationalization: Working with financial advisors on strategic alternatives, including divestitures, and completing a company-wide review to streamline operations.

View in transcript ↓

Segment performance

In academia and government, Clarivate recently moved to a subscription-only strategy for ProQuest ebooks and digital collections, phasing out one-time transactional sales by end-2025. ProQuest ebooks is the world's largest subscription of academic ebooks with over 700,000 titles. In life science, the company launched DRG Fusion, a modular subscription-based real-world data analytics product, and plans to wind down real-world data direct licenses by Q4 2026. Q4 revenue was $663 million, full year $2.56 billion. Recurring revenue mix was 80% in 2024, with plans to increase to 87% and higher.

View in transcript ↓

Guidance

2025 Guidance - ACV expected to accelerate by ~60 basis points to 1.5% midpoint. - Recurring organic growth flat midpoint. - Revenue expected ~$2.34B midpoint due to strategic disposals, prior divestitures, and stronger USD. - Adjusted EBITDA range $940M-$1B, profit margin 41.5%. - Diluted adjusted EPS $0.60-$0.70. - Free cash flow ~$340M midpoint.

View in transcript ↓

Risks

Risks - Exposure to federal and state government spending cuts, especially in academia and government solutions. - Foreign exchange headwind due to strong USD affecting top and bottom line.

View in transcript ↓

Q&A highlights

Q: Thoughts on revenue synergy potential between business lines and new products being TAM extension or value-added.

A: Matti said new products are both TAM extensions and value-added, with examples like AI enablement in web of science and new IP products.

Q: Organic ACV inflection in 2025 and strategic review criteria.

A: Jonathan said ACV inflection from combination of new product investments and VCP strategic disposals; strategic review criteria include monetizing valuable assets and considering segment separability.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$0.21$0.20+5.0%
Revenue$663.0M$601.1M+10.3%

Transcript

February 19, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.